A real-world nomogram integrating predictive markers for disease-free survival in postmenopausal triple-negative breast cancer receiving anthracycline/taxane-based chemotherapy

Background

Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis, especially in postmenopausal women who are routinely treated with anthracycline/taxane-based chemotherapy. However, wide inter-individual variation in disease-free survival (DFS) underscores an urgent need for reliable predictive markers and practical prognostic tools. We aimed to develop and validate a real-world nomogram that integrates clinically accessible predictive markers for individualised DFS prediction in this specific population.